Dual Programmed Death Receptor‐1 and Vascular Endothelial Growth Factor Receptor‐2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma
Kohei Shigeta(Massachusetts General Hospital), Dan G. Duda(Massachusetts General Hospital)
Cited by 404
Related Papers
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
|Angiogenesis|2017|690
CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice
|Hepatology|2014|456
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
|Journal for ImmunoTherapy of Cancer|2020|149